Drug Type Autologous CAR-T |
Synonyms HER2 CAR-iNKT(BrightPath Biotherapeutics), BP 2301, BP2301 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Female Genital Neoplasms | Phase 1 | - | - | |
Osteosarcoma | Phase 1 | - | - |